A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Provision of written informed consent. * ≥ 20 years of age * Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI503 dose * Females of childbearing potential must have a negative serum pregnancy test * Adequate organ function * Life expectancy ≥ 3 months Exclusion Criteria: * Any known symptomatic or untreated brain metastases * Pregnant or breastfeeding * Crohn's disease, ulcerative colitis extensive gastric and small intestine resection * Unable or unwilling to swallow BBI503 daily * Uncontrolled concurrent disease * Received other investigational drugs within 4 weeks prior to first dose * Prior treatment with BBI503